Nemaura Medical Announces Receipt of Notice from Nasdaq
09 mars 2023 16h57 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, March 09, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...
Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
24 févr. 2023 09h00 HE
|
Nemaura Medical, Inc
Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference
16 févr. 2023 08h15 HE
|
Nemaura Medical, Inc
Loughborough, England, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable sensors...
Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
31 janv. 2023 13h50 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...
Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
27 janv. 2023 08h20 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...
Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet
26 janv. 2023 08h00 HE
|
Nemaura Medical, Inc
Nemaura to integrate its proBEATTM glucose sensors with HealthFleet’s proven RestoreHealth wellness program targeted at U.S. market LOUGHBOROUGH, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical,...
Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants
24 janv. 2023 08h00 HE
|
Nemaura Medical, Inc
Average weight loss of 3.7 pounds and an average BMI reduction of 0.6 after 10 weeks in initial patients LOUGHBOROUGH, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:...
Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference
11 janv. 2023 08h00 HE
|
Nemaura Medical, Inc
Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic...
Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022
01 déc. 2022 08h15 HE
|
Nemaura Medical, Inc
Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic...
Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom
29 nov. 2022 08h00 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...